Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

5247 - Mixed Adeno-Neuroendocrine Carcinoma (MANEC) of the gastroenteropancreatic (GEP) tract: a multicentre retrospective study

Date

10 Sep 2017

Session

Poster display session

Presenters

Melissa Frizziero

Citation

Annals of Oncology (2017) 28 (suppl_5): v142-v157. 10.1093/annonc/mdx368

Authors

M. Frizziero1, X. Wang2, B. Chakrabarty3, A. Childs4, T.V. Luong5, T. Walter6, M. Elshafie7, T. Shah8, P. Fulford9, A. Minicozzi9, W. Mansoor1, T. Meyer10, R.A. Hubner1, J.W. Valle11, M.G. McNamara1

Author affiliations

  • 1 Department Of Medical Oncology, The Christie NHS Foundation Trust, M206SL - Manchester/GB
  • 2 Department Of Analytics And Development, The Christie NHS Foundation Trust, M206SL - Manchester/GB
  • 3 Department Of Pathology, The Christie NHS Foundation Trust, M206SL - Manchester/GB
  • 4 Medical Oncology, Royal Free London NHS Foundation Trust, NW3 2QG - London/GB
  • 5 Department Of Histopathology, Royal Free Hospital, NW3 2QG - London/GB
  • 6 Gastroenterology And Medical Oncology, Hospices Civils de Lyon, Lyon1 University, 69437 - Lyon/FR
  • 7 Department Of Pathology, University Hospital of Birmingham NHS Foundation Trust, B15 2TH - Birmingham/GB
  • 8 Department Of Hepatology, University Hospital of Birmingham NHS Foundation Trust, B15 2TH - Birmingham/GB
  • 9 Department Of Surgical Oncology, The Christie NHS Foundation Trust, M206SL - Manchester/GB
  • 10 Department Of Medical Oncology, Royal Free London NHS Foundation Trust, NW3 2QG - London/GB
  • 11 Medical Oncology, The Christie NHS Foundation Trust, M206SL - Manchester/GB
More

Resources

Abstract 5247

Background

MANEC is a rare entity and evidence on its prognosis and management is limited.

Methods

Demographic/clinicopathological/survival data of consecutive patients (pts) with a diagnosis of MANEC (2010 WHO criteria) from 4 European centres were retrospectively reviewed.

Results

Fifty-three pts were identified (01/06-03/17); median (med) age: 62 yrs (range 34-89), male: 70%, ECOG PS 0-1: 60%, with primary tumours from small/large bowel in 34 (64%), oesophagus/stomach: 13 (24.5%), pancreas/biliary tract: 5 (9.5%), unknown (UNK): 1 (2%). Forty percent had an adult comorbidity evaluation (ACE)-27 score of 0. The neuroendocrine (NE) component (predominant histology in 40%) was poorly-differentiated (PD) in 45 (85%) [Ki-67≥55%: 58%]. Most frequently-expressed immunohistochemical (IHC) markers were synaptophysin (100%), chromogranin A (CgA) (58.5%) and CDX2 (51%). Histology was PD NE in 64% from recurrent/metastatic sites (n = 14 pts). Of 28 (53%) pts with localised disease (LA), 26 (93%) had curative surgery (7 had neoadjuvant chemo-radiotherapy (CT-RT), 6 adjuvant CT, 1 peri-operative CT), 1 (3.5%) had definitive CT-RT and 1 (3.5%) had UNK management; 16 (57%) recurred. Forty-one pts (77%) were treated for advanced (adv) disease: 20 (49%) platinum-based CT, 3 (7%) irinotecan-based CT, 1 (2.4%) gemcitabine, 3 (7%) UNK CT regimen, 1 (2.4%) RT, 1 (2.4%) CT-RT, 11 (27%) best supportive care (BSC), and 1 (2.4%) UNK management. Med follow-up time was 10.4 months (mo) (95% Confidence Interval (CI) 5.15-13.09). Med overall survival (OS) for all pts was 18.6 mo (95% CI 11.4-40). Med recurrence-free survival and OS in pts with LA was 19.4 mo (95%CI 5.8-30.9) and 21 mo (95%CI 12.1-40). Med progression free survival (PFS) and OS in pts with adv disease was 4.6 mo (95%CI 3.3-6.7) and 13.6 mo (95%CI 8.8-33.1). On univariable analysis, ACE-27 score (0 vs ≥ 1) was prognostic for better PFS and OS (both p 

Conclusions

PD NE histology in MANECs was predominant in both diagnostic and recurrent/metastatic tumour samples. Active treatments were offered to most pts but more effective therapy is clearly needed.

Clinical trial identification

Legal entity responsible for the study

The Christie NHS Foundation Trust

Funding

The Christie

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.